Prescription medicine
Ubrogepant Brand names: Ubrelvy
Ubrogepant (Ubrelvy) is a prescription medicine with an FDA approval on record since 2019. No generic is listed; pharmacies paid $109.11 per Ubrelvy 100 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the ubrogepant FDA label on DailyMed (effective June 5, 2025, Allergan, Inc.); the NDA 211765 record on Drugs@FDA; every ubrogepant label on DailyMed.
Highlights of the record
FDA label of June 5, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageUBRELVY is indicated for the acute treatment of migraine with or without aura in adults.
Forms and strengths
- 50 mg
- 100 mg
Tablet.
On the market
- Earliest approval on file
- December 23, 2019 Ubrelvy, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- December 22, 2041 Ubrelvy tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $109.11 per tablet Ubrelvy 100 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is ubrogepant used for?
From the label: indications and usageUBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine.
Conditions named in the indications of ubrogepant's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Calcitonin Gene-related Peptide Receptor Antagonist.
Source: FDA drug label (UBRELVY), NDA211765 (Abbvie), as published by Allergan, Inc., effective June 5, 2025 (SPL set fd9f9458-fd96-4688-be3f-f77b3d1af6ab), via openFDA; the full label on DailyMed
Is there a generic for ubrogepant (Ubrelvy)?
No generic ubrogepant is approved (Drugs@FDA, October 8, 2026). Drugs@FDA also holds 2 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
The Orange Book lists 16 patents for Ubrelvy tablets: the compound patent runs to December 23, 2033, and the last listed entry to December 22, 2041. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2019 earliest approval on file
- 2041 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for ubrogepant (Ubrelvy)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $109.11 per Ubrelvy 100 mg tablet, up 5% from $103.95 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ubrelvy 100 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ubrelvy 100 mg tablet | Brand | $109.11 per tablet | $3,273.21 | +5% |
| Ubrelvy 50 mg tablet | Brand | $108.89 per tablet | $3,266.72 | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the ubrogepant label say about other medicines?
The ubrogepant label names 13 other medicines in its interaction, contraindication or warning sections. The labels of 1 other medicine name ubrogepant. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Carvedilol | drug interactions | Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ]. |
| Ciprofloxacin | drug interactions | Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )]. |
| Clarithromycin | drug interactions | UBRELVY should not be used with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) [see Contraindication s ( 4 )]. |
| Cyclosporine | drug interactions | Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )]. |
| Eltrombopag | drug interactions | Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ]. |
| Fluconazole | drug interactions | Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )]. |
| Fluvoxamine | drug interactions | Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) [see Dosage and Administration ( 2.2 )]. |
| Itraconazole | drug interactions | UBRELVY should not be used with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) [see Contraindication s ( 4 )]. |
| Ketoconazole | drug interactions | CYP3A4 I nhibitors Co-administration of UBRELVY with ketoconazole, a strong CYP3A4 inhibitor, resulted in a significant increase in exposure of ubrogepant [see Clinical Pharmacology ( 12.3 ) ]. |
| Phenytoin | drug interactions | In patients taking strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John’s Wort), loss of ubrogepant efficacy is expected, and concomitant use should be avoided. |
| Quinidine | drug interactions | Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ]. |
| Rifampin | drug interactions | CYP3A4 I nducers Co-administration of UBRELVY with rifampin, a strong CYP3A4 inducer, resulted in a significant reduction in ubrogepant exposure [ s ee Clinical Pharmacology ( 12.3 ) ]. |
| Verapamil | drug interactions | Co-administration of UBRELVY with verapamil, a moderate CYP3A4 inhibitor, resulted in an increase in ubrogepant exposure [see Clinical Pharmacology ( 12.3 ) ]. |
Other labels that name ubrogepant
Source: FDA drug label (UBRELVY), NDA211765 (Abbvie), as published by Allergan, Inc., effective June 5, 2025 (SPL set fd9f9458-fd96-4688-be3f-f77b3d1af6ab), via openFDA; the full label on DailyMed
What else is labeled for the same conditions as ubrogepant?
12 other medicines are given the same way (oral) and in the same FDA class as ubrogepant or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Atogepant | Migraine | none listed | $38.36 per tablet 10 mg tablet | No current entry |
| Rimegepant | Migraine | none listed | $128.67 per tablet 75 mg tablet | No current entry |
| Sumatriptan | Migraine | 22 labelers | $0.302 per tablet 50 mg tablet | No current entry |
| Rizatriptan | Migraine | 25 labelers | $0.335 per tablet 10 mg tablet | No current entry |
| Zolmitriptan | Migraine | 18 labelers | $1.02 per tablet 2.5 mg tablet | No current entry |
| Eletriptan | Migraine | 10 labelers | $1.75 per tablet 40 mg tablet | No current entry |
| Naratriptan | Migraine | 4 labelers | $1.08 per tablet 2.5 mg tablet | No current entry |
| Almotriptan | Migraine | 3 labelers | $16.86 per tablet 12.5 mg tablet | No current entry |
Every medicine labeled for the same conditions as ubrogepant
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to ubrogepant
- 12 medicines for the same use
- Other calcitonin gene-related peptide receptor antagonists
- the pharmacologic class, with prices and generics
- Check an interaction
- what two or more labels say about each other